 | | Vol. 9.32 – 26 August, 2020 |
| |
|
|
| Detailed metabolomic analysis revealed elevated nicotinamide metabolism in relapsed leukemia stem cells (LSCs), which activated both amino acid metabolism and fatty acid oxidation to drive OXPHOS, thereby providing a means for LSCs to circumvent the cytotoxic effects of venetoclax and azacitidine therapy.
[Cell Stem Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| In an MLL-AF9 AML mouse model, genetic deletion of β-catenin, or even all four Tcf/Lef family transcription factors that interact with β-catenin, did not affect AML onset in primary recipients, or the ability of leukemic stem cells in propagating AML in secondary recipients.
[eLife] |
|
|
|
| Functional studies showed that E2F7 promoted cell proliferation, cell-cycle progression, cell metastasis and tumorigenicity abilities in vitro and in vivo.
[British Journal of Cancer] |
|
|
|
| The authors performed in vitro and in vivo experiments and six human IDH1/2 wild-type glioblastoma stem-like cells were established and studied to determine a potential interaction of YKL-40 and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation.
[Cell Death & Disease] |
|
|
|
| Researchers discovered that increased iroquois-class homeodomain protein 4 (IRX4) was related to gefitinib resistance in non-small cell lung cancer (NSCLC) cells. Knockdown of IRX4 inhibited cell proliferation, sphere formation, and the expression of CD133, ALDH1A1, NANOG, Sox2 and Notch1, and the transcriptional activity of NANOG promoter.
[Cell Death & Disease] |
|
|
|
| Investigators demonstrated that exon-v6 specific removal from CD44v isoforms increases cell sensitivity to cisplatin and impairs gastric cancer cells self-renewal.
[Cancers] |
|
|
|
| Infection of patient-derived glioma cells with adenovirus (ADV) increased the formation of tumor spheres. ADV infection upregulated stem cell markers and in turn promoted the capacities of self-renewal and multi-lineage differentiation of the infected tumor spheres.
[Cell Communication and Signaling] |
|
|
|
| Scientists captured circulating tumor cells (CTCs) from the peripheral blood of breast cancer patients using size‐exclusion membranes followed by scRNA‐seq of enriched CTCs and carry‐over peripheral blood mononuclear cells.
[Molecular Carcinogenesis] |
|
|
|
| In vitro behavior of FACS‐sorted CD44HighESAHigh CSCs and CD44HighESALow CSCs from oral squamous cell carcinoma cells was characterized by their ability to form colonies, migrate, proliferate, and to invade a solid matrix.
[Journal of Oral Pathology & Medicine] |
|
|
|
| The authors investigated the associations between genetic information and the various leukemic stem cell (LSC) phenotypes, namely multipotent progenitor-like, lymphoid primed multipotent progenitor-like and granulocyte-macrophage progenitors-like LSC in 52 acute myeloid leukemia patients.
[Korean Journal of Internal Medicine] |
|
|
|
| Researchers evaluated in vitro, the effects of photobiomodulation (PBM), with the same dosimetric parameters as those used in the clinic for oral mucositis prevention and treatment, on oral squamous cell carcinoma cellular viability, as well as PBM’s effect on cancer stem cell properties and its phenotype.
[Lasers in Medical Science] |
|
|
|
|
| Investigators review the expression of oral mucosal stem cell markers in oral submucous fibrosis (OSF), oral potentially malignant disorders and oral squamous cell carcinoma to understand the role of basal cells in potentiating cancer stem cell behaviour in OSF.
[International Journal of Oral Science] |
|
|
|
| The authors summarize the recent discoveries involving metabolism and tumor metastasis, and emphasize the promising molecular targets, with an update on the development of small molecule or biologic inhibitors against these aberrant situations in cancer.
[Oncogene] |
|
|
|
|
| Novartis announced that, at primary analysis, the Phase III ASCEMBL study met its primary endpoint of statistically significant superiority in major molecular response rate at 24 weeks for asciminib vs. bosutinib.
[Novartis AG] |
|
|
|
| Primary HLH is a family of devastating primary immune deficiencies with limited treatment options and no gene therapies under clinical testing. Expression Therapeutics has developed a promising and potentially curative gene therapy candidate for familial HLH type 3.
[Expression Therapeutics (PR Newswire Association LLC.)] |
|
|
|
|
|
|
|
| | Sanford Burnham Prebys Medical Discovery Institute – La Jolla, California, United States |
|
|
|
| | Northwestern University – Chicago, Illinois, United States |
|
|
|
| | The University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
| | Cincinnati Children’s Hospital Medical Center – Cincinnati, Ohio, United States |
|
|
|
| | West Virginia University – Morgantown, West Virginia, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
